IRLAB publishes recorded speech and company presentation prior to digital AGM
IRLAB (Nasdaq Stockholm: IRLAB A) announced today that a video recording for the digital annual general meeting (AGM) 2021 is available on the company's website, www.irlab.se. The video recording includes a speech from the Chair of the board, presentation of the newly proposed board member and company presentation. The video is intended to provide information to shareholders as a basis for the digital postal voting, which is ongoing until 5 May 2021.
Due to the continued spread of Covid-19 and to ensure the safety of our shareholders, the annual general meeting will this year be held without physical presence, as previously announced.
Participation at the annual general meeting will instead occur by using a digital postal voting form, available on www.irlab.se in the menu ‘Corporate Governance’ or through the following link: www.bit.ly/IRLAB-AGM21.
For more information
Nicholas Waters, CEO
Phone: +46 730 75 77 01
E-mail: [email protected]
Viktor Siewertz, CFO
Phone: +46 727 10 70 70
E-mail: [email protected]
IRLAB is a Swedish research and development company that focuses on developing novel treatments in Parkinson’s disease. The company's most advanced candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which completed Phase IIa studies, intends to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PD-P) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through the proprietary research platform, ISP (The Integrative Screening Process), IRLAB discovers and develops unique drug candidates for central nervous system (CNS) related disorders where large and growing medical need exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. IRLAB is listed on Nasdaq Stockholm Main Market. More information on www.irlab.se.
Nexstim granted authorization for commercial distribution of NBS system in Australia
Nexstim’s NBS System is the only FDA cleared system based on navigated Transcranial Magnetic Stimulation (nTMS) for non-invasive mapping of the speech and motor cortices of the brain. The NBS system is used, for example, after a patient has had a diagnosis of a brain tumor or other disorder and when...
FluoGuide has received green light to proceed to the next dose level with FG001 in the ongoing clinical phase I/II trial in patients undergoing surgical treatment of high grade glioma.
Copenhagen, Denmark, 18 May 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the dose escalation committee has reviewed the data from the fifth dose level and approved initiation of the next dose level. In addition, the company has received approval to commence w...
Qlife’s styrelse och ledning nyttjar innehavda teckningsoptioner av serie TO1 för 2,4 MSEK
Innehavare av teckningsoptioner äger rätt att för varje två (2) ägda teckningsoption av serie TO1 teckna en (1) ny aktie i Qlife till ett pris om 17,50 SEK per aktie. Antalet teckningsoptioner av serie TO1 som har utnyttjats av ledamöter i styrelsen och medlemmar av ledningen uppgår till 269 352, mo...
Qlife's Board of Directors and management exercise warrants of series TO1 for SEK 2.4 million
The warrant holders have the right to subscribe for one (1) new share in Qlife for each two (2) owned warrants of series TO1 at a price of SEK 17.50 per share. The number of warrants of series TO1 that have been exercised by members of the Board of Directors and management amounts to 269,352, corres...